ReviewInternational journal of cancer2026
The role of cytokines in ovarian cancer drug resistance.
Review in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of cytokines in ovarian cancer drug resistance.International journal of cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients initially respond to treatment and may experience tumor regression, 80% of patients relapse after one or multiple chemotherapy sessions. Cytokines play a crucial role in driving tumor progression, relapse, and drug resistance in ovarian cancer. The knowledge of ovarian cancer drug resistance and the function of cytokines in the development of tumor resistance is currently the subject of numerous relevant studies; meanwhile, the specific molecular pathways are being unearthed. Herein, we summarize the recent advancements in cytokine-associated ovarian cancer drug resistance. In addition, we also present the cytokine targeting drugs in ameliorating ovarian cancer drug resistance. As multi-effect factors, cytokines can induce multiple pathways to promote tumor progression and overcome extremely complex and heterogeneous living environments. From the perspective of various paths of cytokine function, the emergence of multi-target drugs might be more promising for conquering ovarian cancer chemotherapy drug resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.